TD Cowen raised the firm’s price target on CME Group (CME) to $328 from $305 and keeps a Buy rating on the shares. The firm said they exit 4Q25 earnings and post conference call still constructive on the shares reflecting the combination of favorable cyclical dynamics plus widening structural growth potential.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group price target raised to $340 from $319 at Morgan Stanley
- CME Group: Resilient Fee-Based Franchise with Defensive Strengths and Underappreciated Structural Growth Justifies Buy Rating
- CME Group price target raised to $312 from $304 at Barclays
- CME Group reports Q4 adjusted EPS $2.77, consensus $2.74
- These Are the Stocks Reporting Earnings Today – February 4, 2026